Search News Year All202620252024202320222021 06/11/2026 Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition Read More 06/08/2026 Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA Read More 05/29/2026 Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read More 05/12/2026 Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference Read More 05/06/2026 Zevra Reports First Quarter 2026 Financial Results and Corporate Update Read More 04/22/2026 Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call Read More 03/20/2026 Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) Read More 03/16/2026 Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million Read More 03/09/2026 Zevra Reports Fourth Quarter and Full Year 2025 Financial Results Read More 03/05/2026 Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer Read More
06/11/2026 Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition Read More
06/08/2026 Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA Read More
05/29/2026 Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read More
05/12/2026 Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference Read More
03/20/2026 Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) Read More
News
Careers
Contacts